Skip to main content
Clinical Trials/IRCT2014012616374N1
IRCT2014012616374N1Completed未知

The effect of bumetanide on positive , negative and cognitive symptoms of schizophrenic patients

Vice chancellor for research, university of Social Welfare & Rehabilitation sciences0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 55 years (—)
Sex
All

Inclusion Criteria

  • inclusion criteria: (1) Diagnosis of schizophrenia at any subtype according to DSM-IV diagnosis an statistical manual of mental disorders, 4th edition (2) aged 20 to 70 years (3) disease duration for at least 3 years (4) had a total score of at least 70 on the positive and negative syndrome scale(PANSS) (5) had persistent negative or considerable cognitive symptoms, that are equivalent with at least 20 and 15 score on the negative and cognitive subscales of PANSS, respectively. Exclusion criteria were: patients with a (1) documented fluctuation in symptoms (2) uncontrollable significant conditions (3) As well as concurrent history of significant psychiatric (except schizophrenia), cardiovascular, renal, hepatic, convulsive disorders or substance abuse.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Vice chancellor for research, university of Social Welfare & Rehabilitation sciences

Similar Trials